Cargando…

Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer

Updates from the phase III KEYNOTE-522 and KEYNOTE-355 trials demonstrate the benefits of pembrolizumab added to chemotherapy in early-stage and locally advanced or metastatic triple-negative breast cancer, respectively.

Detalles Bibliográficos
Autor principal:	Jacobson, Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Conference Perspectives: Highlights from SABCS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963307/ https://www.ncbi.nlm.nih.gov/pubmed/35348777 http://dx.doi.org/10.1093/oncolo/oyac014

Ejemplares similares

Early Switch to Fulvestrant Plus Palbociclib Improves Outcomes in ESR1-Mutated, Estrogen Receptor-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Pyrotinib Improves Survival in Previously Treated HER2-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Ribociclib Improves Overall Survival in HR+/HER2– Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
por: Jacobson, Anne
Publicado: (2022)

Trastuzumab Deruxtecan Improves Progression-Free Survival and Intracranial Response in Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases
por: Jacobson, Anne
Publicado: (2022)

Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2– Advanced Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Benefits of Adjuvant Chemotherapy Differ by Menopausal Status in Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Recurrence Score
por: Jacobson, Anne
Publicado: (2022)

SABCS 2021 Insights on Breast Cancer Research: An Interview with Dr. Laura Spring
por: Jacobson, Anne
Publicado: (2022)

Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab
por: Bagegni, Nusayba A, et al.
Publicado: (2022)

Immunotherapy for early triple negative breast cancer: research agenda for the next decade
por: Tarantino, Paolo, et al.
Publicado: (2022)

Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer
por: Wang, Dong, et al.
Publicado: (2017)

Advances in the Management of Early-Stage Triple-Negative Breast Cancer
por: Bhardwaj, Prarthna V., et al.
Publicado: (2023)

Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States
por: Huang, Min, et al.
Publicado: (2023)

Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm
por: Olivier, Timothee, et al.
Publicado: (2021)

Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer
por: Anders, Carey K, et al.
Publicado: (2022)

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
por: Egelston, Colt A., et al.
Publicado: (2023)

Complete Response of Triple-Negative Metaplastic Carcinoma of the Breast Using Pembrolizumab
por: Ladwa, Amrita, et al.
Publicado: (2023)

Conceptualizing the complexity of ferroptosis to treat triple-negative breast cancer: theory-to-practice
por: Zhang, Hang, et al.
Publicado: (2023)

Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
por: Takahashi, Masato, et al.
Publicado: (2023)

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
por: Chun, Brie, et al.
Publicado: (2022)

Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab
por: Routh, Eric D, et al.
Publicado: (2023)

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer
por: Yau, Christina, et al.
Publicado: (2010)

Overview of recent advances in metastatic triple negative breast cancer
por: O'Reilly, David, et al.
Publicado: (2021)

Margetuximab: An active alternative for later‐line therapy in patients with HER2‐positive advanced breast cancer
por: Zhou, Yunxiang, et al.
Publicado: (2023)

Tips and tricks in triple-negative breast cancer: how to manage patients in real-life practice?
por: Piccart, M, et al.
Publicado: (2011)

Improving Early Initiation of Breastfeeding in Southeast Asia: The Alive & Thrive Experience
por: Granger, Kristina
Publicado: (2018)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
por: Shah, Ami N, et al.
Publicado: (2020)

GD2+ cancer stem cells in triple-negative breast cancer: mechanisms of resistance to breast cancer therapies
por: Nguyen, Khoa, et al.
Publicado: (2022)

Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study
por: de la Cruz-Merino, Luis, et al.
Publicado: (2021)

Translating the role of PARP inhibitors in triple-negative breast cancer
por: Beniey, Michèle, et al.
Publicado: (2019)

Novel therapy for locally advanced triple-negative breast cancer
por: YAMADA, ATSUKO, et al.
Publicado: (2015)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Registry Study Describes COVID‐19 Mortality and Hospitalization in Patients with Breast Cancer
Publicado: (2021)

Breast Cancer Chemotherapy Can Be Administered Safely During the COVID‐19 Pandemic
Publicado: (2021)

JUPITER‐02 trial: advancing survival for recurrent metastatic nasopharyngeal carcinoma and next steps
por: Tan, Laura Ling Ying, et al.
Publicado: (2021)

Futility versus utility of marrow assessment in initial Ewing sarcoma staging workup
por: Anderson, Peter M
Publicado: (2015)

Triple negative breast cancer: looking for the missing link between biology and treatments
por: Palma, Giuseppe, et al.
Publicado: (2015)

Is breast conservation superior to mastectomy in early stage triple negative breast cancer?
por: Saifi, Omran, et al.
Publicado: (2022)

Guards! Guards! How innate lymphoid cells ensure local law and order
por: Häfner, Sophia Julia
Publicado: (2021)

CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data
por: Zujewski, Jo Anne, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_t1ontflec3pqthar6v9tp911j7